RXST INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead the RxSight Class Action Lawsuit

Key Takeaways:

• Class Action Initiated: A lawsuit filed against RxSight alleges violations of securities laws.
• Alleged Misleading Statements: The company’s executives are accused of providing false information.
• Investor Losses: Shareholders who suffered substantial losses may be eligible to participate.
• Action Deadline: Lead plaintiff motions must be filed by September 22, 2025.
• Company Profile: RxSight specializes in light adjustable intraocular lenses for cataract surgery.

RxSight Sued: Class Action Alleges Securities Law Violations

Robbins Geller Rudman & Dowd LLP Files Lawsuit on Behalf of Investors

Robbins Geller Rudman & Dowd LLP announced the filing of a class action lawsuit against RxSight, Inc. (NASDAQ: RXST), alleging that certain top executives violated the Securities Exchange Act of 1934 by making false and misleading statements. The lawsuit, captioned Makaveev v. RxSight, Inc. , No. 25-cv-01596 (C.D. Cal.), seeks to represent investors who purchased or acquired RxSight securities and suffered substantial losses.

Company Background

RxSight is a commercial-stage medical technology company engaged in the research, development, manufacture, and sale of light adjustable intraocular lenses (LALs) used in cataract surgery. The company’s innovative LAL technology allows ophthalmologists to make adjustments to the lens after implantation, aiming to improve postoperative visual outcomes for patients.

Allegations of Misleading Statements

The lawsuit alleges that RxSight’s top executives made false and/or misleading statements regarding the company’s business operations and prospects. Specifically, it claims that these executives provided inaccurate information that artificially inflated the company’s stock price, misleading investors about the true state of RxSight’s financial health and performance.

Impact on Investors

As a result of the alleged misconduct, investors who purchased or acquired RxSight securities at inflated prices may have incurred significant financial losses. The lawsuit contends that these investors were not provided with accurate information necessary to make informed investment decisions, constituting a violation of federal securities laws.

Legal Actions and Deadlines

Robbins Geller Rudman & Dowd LLP encourages affected investors to consider serving as lead plaintiffs in the class action lawsuit. The deadline for filing lead plaintiff motions is September 22, 2025. Interested parties can submit their information through the law firm’s website or contact attorneys J.C. Sanchez or Jennifer N. Caringal directly by calling 800/449-4900 or emailing info@rgrdlaw.com.

Investor Call to Action

Investors who have suffered substantial losses have the opportunity to join the lawsuit and seek compensation for their damages. Participating in the legal action may also contribute to holding the company’s executives accountable for the alleged violations and promoting greater transparency in corporate communications.

Conclusion

The class action lawsuit against RxSight brings serious allegations to light, raising concerns about corporate governance and investor relations within the company. As the legal proceedings unfold, the situation remains one to watch for shareholders and those interested in corporate accountability. Investors are advised to stay informed and consider their legal options before the approaching deadline.